levocabastine
Sign in to saveAlso known as LIV121
Levocabastine (trade name Livostin or Livocab, depending on the region) is a selective second-generation H1 receptor antagonist which was discovered at Janssen Pharmaceutica in 1979. It is used for allergic conjunctivitis.
Research
323 papers- Levocabastine.2006
- Levocabastine: an effective topical treatment of allergic rhinoconjunctivitis.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 1991
- Levocabastine. An update of its pharmacology, clinical efficacy and tolerability in the topical treatment of allergic rhinitis and conjunctivitis.Drugs · 1995
- Levocabastine eye drops: a new approach for the treatment of acute allergic conjunctivitis.European journal of ophthalmology · 1994
- Levocabastine. A review of its pharmacological properties and therapeutic potential as a topical antihistamine in allergic rhinitis and conjunctivitis.Drugs · 1991
via PubMed
~1 min read
Encyclopedic overview
2 sectionsContents
- References
- External links
Levocabastine (trade name Livostin or Livocab, depending on the region) is a selective second-generation H1 receptor antagonist which was discovered at Janssen Pharmaceutica in 1979. It is used for allergic conjunctivitis.
As well as acting as an antihistamine, levocabastine has also subsequently been found to act as a potent and selective antagonist for the neurotensin receptor NTS2, and was the first drug used to characterise the different neurotensin subtypes. This has made it a useful tool for the study of this receptor.
Excerpted from Wikipedia’s “levocabastine” article, available under the CC BY-SA 4.0 licence.
Available in 12 languages
via Wikidata sitelinks · CC0